Ebusua Fie

Honorable Mention Inspired by the Fanti of Ghana. What inspired you to enter this special competition to create a modern architectural language for Africa? Growing up in the Caribbean and currently living in Ghana, I‘ve been interested in the conversation surrounding the development and definition of both a Caribbean‘ style and African‘ style and the cultural, social, political and historical issues that surround this. The competition seemed like a perfect avenue to continue to investigate these interests. What did you find most interesting or challenging during the research and development of your prototype? Trying to study and investigate the traditional models and interpreting into a modern manifestation without replicating, or tacking on traditional elements without rigor and purpose.Also, getting the people I‘ve engaged with to understand that buildings utilizing earth or other locally sourced materials are NOT synonymous with poverty. When they‘ve seen images they realizeitcanbebeautifulandwell executed with today‘s technologicaladvances. Why do you believe African homeowners will be interested in building a home such as the one you have submitted today? A prospective homeowner would choose to buy this home design due to the following factors: It is environmentally sustainable, reducing homeowner‘s reliance on air conditioning thereby reducing life cycle costs; References traditional values in terms of community and family relationships while maintaining privacy; Small footprint, allowing building in more dense areas or on smaller plots of land

Immunosuppressive mechanisms in glioblastoma

Despite maximal surgical and medical therapy, the treatment of glioblastoma remains a seriously vexing problem, with median survival well under 2 years and few long-term survivors. Targeted therapy has yet to produce significant advances in treatment of these lesions in spite of advanced molecular characterization of glioblastoma and glioblastoma cancer stem cells. Recently, immunotherapy has emerged as a promising mode for some of the hardest to treat tumors, including metastatic melanoma. Although immunotherapy has been evaluated in glioblastoma in the past with limited success, better understanding of the failures of these therapies could lead to more successful treatments in the future. Furthermore, there is a persistent challenge for the use of immune therapy to treat glioblastoma secondary to the existence of redundant mechanisms of tumor-mediated immune suppression. Here we will address these mechanisms of immunosuppression in glioblastoma and therapeutic approache

Current Options and Future Directions in Immune Therapy for Glioblastoma

Glioblastoma is in need of innovative treatment approaches. Immune therapy for cancer refers to the use of the body's immune system to target malignant cells in the body. Such immune therapeutics have recently been very successful in treating a diverse group of cancerous lesions. As a result, many new immune therapies have gained Food and Drug Administration approval for the treatment of cancer, and there has been an explosion in the study of immune therapeutics for cancer treatment over the past few years. However, the immune suppression of glioblastoma and the unique immune microenvironment of the brain make immune therapeutics more challenging to apply to the brain than to other systemic cancers. Here, we discuss the existing barriers to successful immune therapy for glioblastoma and the ongoing development of immune therapeutics. We will discuss the discovery and classification of immune suppressive factors in the glioblastoma microenvironment; the development of vaccine-based therapies; the use of convection-enhanced delivery to introduce tumoricidal viruses into the tumor microenvironment, leading to secondary immune responses; the emerging use of adoptive cell therapy in the treatment of glioblastoma; and future frontiers, such as the use of cerebral microdialysis for immune monitoring and the use of sequencing to develop patient-specific therapeutics. Armed with a better understanding of the challenges inherent in immune therapy for glioblastoma, we may soon see more successes in immune-based clinical trials for this deadly disease

Neddylation inhibition upregulates PD‐L1 expression and enhances the efficacy of immune checkpoint blockade in glioblastoma

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/149569/1/ijc32379_am.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/149569/2/ijc32379-sup-0001-Supinfo.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/149569/3/ijc32379.pd

Country of Origin Investment: Experience, Attitudes, and Motivating Factors in the Ghanaian Diaspora

The body of research on the economic activities of diaspora communities has developed over several decades by researchers in a variety of academic disciplines, including economics, sociology, and entrepreneurship. Although international business (IB) research is primarily concerned with the internationalization of large, mature corporations, the cross-border economic activities by individuals, particularly from those who have crossed borders themselves (diasporans) has been identified as a significant gap in the existing body of literature (Cano-Kollmann, Cantwell, Hannigan, Mudambi, & Song, 2016; Ramamurti, 2004, 2011). This dissertation helps to fill this research gap by exploring homeland investment interest (Gillespie, Riddle, Sayre, & Sturges, 1999) in the context of the US-based Ghanaian diaspora. My dissertation makes three specific contributions to the existing international business literature. Firstly, I test the theory of diaspora investment motivation (Nielsen & Riddle, 2010) in a novel environment. Secondly, I draw the distinction between interest in diaspora direct investment and diaspora portfolio investment, identifying key differences in their antecedents. Finally, I investigate how sub-national location affects country of origin investment interest